Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Immunomedics, Inc. was a clinical-stage biopharmaceutical company dedicated to the development of monoclonal antibody-based therapeutics for the targeted treatment of cancer. The company's primary focus was on antibody-drug conjugates (ADCs), a class of potent biopharmaceutical drugs designed as a targeted therapy for treating cancer. Immunomedics' leading product, Trodelvy (sacituzumab govitecan-hziy), received FDA approval for treating metastatic triple-negative breast cancer. In October 2020, Immunomedics was acquired by Gilead Sciences, integrating its innovative ADC platform and oncology pipeline into Gilead's portfolio.
The headquarters served as the central hub for research and development, corporate operations, and manufacturing of its antibody-drug conjugates.
The facility housed state-of-the-art laboratories for biologic drug development, ADC conjugation, and analytical testing, along with capabilities for clinical-scale manufacturing.
Immunomedics fostered a science-driven, innovative, and collaborative work environment. Employees were deeply committed to advancing cancer treatments, driven by a strong sense of purpose to improve patient outcomes.
The Morris Plains headquarters was critical to Immunomedics' success, enabling the discovery, development, and initial manufacturing of Trodelvy and other pipeline ADC candidates.
Prior to its acquisition, Immunomedics' core R&D and manufacturing operations were centered in the United States. The company managed a global clinical trial program for its oncology drug candidates, with sites across North America, Europe, and other key regions. With the advancement of Trodelvy, Immunomedics was actively building its commercial infrastructure to support a global launch, including establishing a European presence.
300 The American Road
Morris Plains
New Jersey
USA
Address: Immunomedics AG, Dammstrasse 19, 6300 Zug, Switzerland (Historical)
To manage European market access, commercialization efforts, medical affairs, and coordinate clinical development programs within the European region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Immunomedics' leadership includes:
Immunomedics has been backed by several prominent investors over the years, including:
In the period leading up to its acquisition by Gilead in October 2020, Immunomedics experienced several key leadership transitions. These changes occurred as the company was advancing its lead drug Trodelvy through late-stage clinical trials, regulatory approval, and preparing for commercial launch.
Discover the tools Immunomedics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Gilead, Immunomedics likely utilized common corporate email formats. The most probable format would combine elements of an employee's name with the company domain.
[first_initial][last]@immunomedics.com
Format
jdoe@immunomedics.com
Example
90%
Success rate
Gilead Sciences / Business Wire • September 13, 2020
Gilead Sciences announced a definitive agreement to acquire Immunomedics for $88.00 per share in cash, valuing the company at approximately $21 billion. The acquisition provided Gilead with Trodelvy, a first-in-class Trop-2 directed antibody-drug conjugate....more
Immunomedics Press Release / FDA • April 22, 2020
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Trodelvy for adult patients with metastatic triple-negative breast cancer (mTNBC) who received at least two prior therapies for metastatic disease. This marked a major milestone for Immunomedics and patients with mTNBC....more
Immunomedics Press Release • July 6, 2020
Immunomedics reported that the confirmatory Phase 3 ASCENT study, evaluating Trodelvy in patients with mTNBC who had received at least two prior therapies, met its primary endpoint of progression-free survival and key secondary endpoints, including overall survival....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Immunomedics, are just a search away.